Ultime notizie per Precigen (NASDAQ:PGEN) Azioni

Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Precigen Inc

Pigeon Corp

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $50 to $57.

News

Price Target

Analyst Ratings

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $57

HC Wainwright &amp; Co. analyst Arthur He reiterates Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) with a Buy and maintains $20 price target.

Reiteration

PSTX

HC Wainwright & Co. Reiterates Buy on Poseida Therapeutics, Maintains $20 Price Target

Barclays analyst Jared Shaw maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Overweight and raises the price target from $56 to $64.

Barclays Maintains Overweight on Synovus Finl, Raises Price Target to $64

Motorola Solutions, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSI#NYSE">MSI</a>) reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com/quote/MSI/earnings">FY24 adjusted EPS guidance above estimates on Thursday.</a>
Motorola Solutions reported quarterly earnings of $3.74 per share which beat the analyst consensus estimate of $3.38 per share. The company reported quarterly sales of $2.79 billion which beat the analyst consensus estimate of $2.76 billion.
&#8220;Our third-quarter results were exceptional, with record Q3 revenue, earnings and cash flow,&#8221; said Greg Brown, chairman and CEO, Motorola Solutions. &#8220;We achieved strong growth across the board, and I&#8217;m pleased with the momentum of our business. As a result, we&#8217;re again raising our revenue and earnings expectations for the full year.&#8221;
Motorola Solutions shares gained 6.8% to trade at $501.80 on Friday.
These analysts made changes to their price targets on Motorola Solutions following earnings announcement.
<ul>
<li>Raymond James analyst Adam Tindle maintained Motorola with an Outperform and raised the price target from $425 to $515.</li>
<li>Barclays analyst Tim Long maintained the stock with an Overweight and raised the price target from $467 to $529.</li>
</ul>
Considering buying MSI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png" alt="" class="wp-image-638367" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08140602/image-95.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Earnings

Markets

Trading Ideas

These Analysts Raise Their Forecasts On Motorola Solutions Following Q3 Earnings

HC Wainwright &amp; Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) with a Buy and maintains $13 price target.

TNGX

HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target

Barclays analyst Julian Mitchell maintains Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Underweight and raises the price target from $245 to $255.

Barclays Maintains Underweight on Rockwell Automation, Raises Price Target to $255

WIIM

Canopy Growth shares are trading lower. The company reported Q2 financial results.

<a href="https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion">https://www.devdiscourse.com/article/technology/3150879-nhtsa-raises-concerns-over-teslas-fsd-promotion</a>
The National Highway Traffic Safety Administration (NHTSA) voiced concerns about Tesla's social media messaging concerning its Full Self-Driving (FSD) software.
NHTSA's worry stems from Tesla's implications that their FSD can be used as a robotaxi, negating the need for constant driver attention. This issue has elevated in importance following an investigation the agency initiated in October into 2.4 million Tesla vehicles equiped with FSD software.
The inquiry came after four reported accidents, including a fatal crash this year. In an email from May 14 released publicly, the NHTSA criticized Tesla's social media announcements for potentially misleading the public into viewing the FSD as anything other than a driver assist system demanding vigilant supervision and occasional driver intervention.

Legal

TSLA

"The National Highway Traffic Safety Administration Expressed Concerns Regarding Tesla's Social Media Posts That Imply Its Full Self-Driving Software Can Function As A Robotaxi Without Driver Supervision. This Comes After The NHTSA Opened An Investigation Into Tesla's FSD Software Following Four Collisions, Including A Fatal Crash In 2023." - Dev Discourse

HC Wainwright &amp; Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) with a Buy and raises the price target from $19 to $20.

RLAY

HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $20

MNMD

Mind Medicine shares are trading higher after the company reported better-than-expected Q3 EPS results.

PRQR

ProQR Therapeutics shares are trading higher afer HC Wainwright & Co. maintained a Buy rating on the stock and raised its price target from $5 to $10.

Needham analyst Laura Martin reiterates Outbrain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OB#NASDAQ">OB</a>) with a Buy and maintains $6 price target.

Needham Reiterates Buy on Outbrain, Maintains $6 Price Target

Over the past 24 hours, Injective's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/inj/usd">INJ</a>) price rose 4.88% to $22.66. This continues its positive trend over the past week where it has experienced a 20.0% gain, moving from $18.77 to its current price. As it stands right now, the coin's all-time high is $52.62. 
The chart below compares the price movement and volatility for Injective over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_0.png" alt="price_chart" />
The trading volume for the coin has increased 55.0% over the past week while the overall circulating supply of the coin has increased 0.0% to over 97.73 million. The current market cap ranking for INJ is #50 at $2.21 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092546_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$INJ

Cryptocurrency Injective Rises More Than 4% In 24 hours

ACHR

Archer Aviation shares are trading higher after the company reported better-than-expected Q3 EPS results.

Barclays analyst Adrienne Yih maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $200 to $257.

Barclays Maintains Overweight on Ralph Lauren, Raises Price Target to $257

ESPR

Esperion Therapeutics shares are trading higher. The stock may be moving on continued strength after reporting better-than-expected Q3 financing results yesterday. Also, HC Wainwright & Co. reiterated a Buy rating on the stock.

Over the past 24 hours, dogwifhat's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) price has fallen 3.22% to $2.31. This is opposite to its positive trend over the past week where it has experienced a 2.0% gain, moving from $2.25 to its current price. 
The chart below compares the price movement and volatility for dogwifhat over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1731092476_0.png" alt="price_chart" />
The trading volume for the coin has increased 63.0% over the past week. while the overall circulating supply of the coin has decreased 0.21% This puts its current circulating supply at an estimated 100.0% of its max supply, which is 998.93 million. The current market cap ranking for WIF is #48 at $2.31 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1731092477_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WIF

Cryptocurrency dogwifhat Down More Than 3% Within 24 hours

Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) reported better-than-expected third-quarter adjusted EPS <a href="https://www.benzinga.com/quote/EXPE/earnings">results on Thursday</a>.
Expedia Group reported quarterly earnings of $6.13 per share which beat the analyst consensus estimate of $6.04 per share. The company reported quarterly sales of $4.06 billion which missed the analyst consensus estimate of $4.11 billion.
&#8220;Our third quarter results exceeded our expectations on gross bookings and earnings with revenue landing in-line. We accelerated bookings growth in our consumer business for the second consecutive quarter, and our advertising and B2B businesses continue to deliver strong double-digit growth,&#8221; said Ariane Gorin, CEO of Expedia Group.
Expedia shares gained 4.8% to trade at $182.45 on Friday.
These analysts made changes to their price targets on Expedia following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d3cdb7b85e930001808a59/daniel-kurnos">Benchmark analyst Daniel Kurnos</a> maintained Expedia with a Buy and raised the price target from $180 to $200.</li>
<li>Wedbush analyst Scott Devitt maintained the stock with a Neutral and raised the price target from $130 to $180.</li>
<li>Oppenheimer analyst Jed Kelly maintained the stock with an Outperform and raised the price target from $155 to $210.</li>
<li>JP Morgan analyst Doug Anmuth maintained Expedia Group with a Neutral and raised the price target from $135 to $170.</li>
<li>BTIG analyst Jake Fuller maintained the stock with a Buy and boosted the price target from $175 to $200.</li>
<li>Barclays analyst Trevor Young maintained Expedia with an Equal-Weight and raised the price target from $134 to $153.</li>
</ul>
Considering buying EXPE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-1024x566.png" alt="" class="wp-image-638359" style="width:534px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08135943/image-94.png 1188w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

EXPE

Expedia Analysts Boost Their Forecasts Following Better-Than-Expected Earnings

Needham analyst Chris Pierce maintains ACV Auctions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) with a Buy and raises the price target from $23 to $26.

ACVA

Needham Maintains Buy on ACV Auctions, Raises Price Target to $26

During the last three months, 10 analysts shared their evaluations of First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated First Horizon and provided 12-month price targets. The average target is $19.75, accompanied by a high estimate of $23.00 and a low estimate of $17.00. Witnessing a positive shift, the current average has risen by 3.4% from the previous average price target of $19.10.
<img src="https://www.benzinga.com/files/images/story/2024/1731092460_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive First Horizon. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.50</td>
<td>$19.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Horizon. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for First Horizon's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into First Horizon's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Horizon analyst ratings.</a>
<h2>Unveiling the Story Behind First Horizon</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
<h3>A Deep Dive into First Horizon's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: First Horizon displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.42%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: First Horizon's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 25.76%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.53%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): First Horizon's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.26%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.22, First Horizon adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 10 Analyst Recommendations For First Horizon

Warning: PGEN is at high risk of performing badly

PGEN

Press Releases

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Comments

Precigen

Notizie

Ultime notizie per Precigen (NASDAQ:PGEN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO